Prognostic Factors and Therapeutic Management of ESBL Enterobacteriaceae in the ICU

Last updated: April 26, 2023
Sponsor: Tourcoing Hospital
Overall Status: Active - Recruiting

Phase

N/A

Condition

N/A

Treatment

N/A

Clinical Study ID

NCT05833282
NRIPH_2023_01
  • Ages > 18
  • All Genders

Study Summary

Multicenter retrospective study conducted in the intensive care units of Tourcoing, Roubaix, and Lille hospitals. Patients hospitalized in the ICU with EBLSE bacteremia within 24 hours before or during their stay in the ICU will be selected from microbiology laboratory data. Patient demographics and clinical data will be collected from the medical record. Microbiological results will be collected from the laboratory data.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Patients admitted to the ICU with EBLSE bacteremia within 24 hours before or duringtheir stay in the ICU.

Exclusion

Exclusion Criteria:

  • Patient who is a minor, protected adult, or who refuses to participate.

Study Design

Total Participants: 500
Study Start date:
July 01, 2022
Estimated Completion Date:
June 30, 2023

Study Description

INCLUSION CRITERIA - Patients admitted to the ICU with EBLSE bacteremia within 24 hours before or during their stay in the ICU.

PRIMARY ENDPOINT

  • The primary endpoint is 30-day mortality.

Connect with a study center

  • Centre Hospitalier DRON

    Tourcoing, 59208
    France

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.